



OPEN

## Impact of salivary and pancreatic amylase gene copy numbers on diabetes, obesity, and functional profiles of microbiome in Northern Japanese population

Takanori Hasegawa<sup>1✉</sup>, Masanori Kakuta<sup>2</sup>, Rui Yamaguchi<sup>2</sup>, Noriaki Sato<sup>3</sup>, Tatsuya Mikami<sup>4</sup>, Koichi Murashita<sup>5</sup>, Shigeyuki Nakaji<sup>6</sup>, Ken Itoh<sup>7</sup> & Seiya Imoto<sup>1✉</sup>

Amylase genes reside in a structurally complex locus, and their copy numbers vary greatly, and several studies have reported their association with obesity. The mechanism of this effect was partially explained by changes in the oral and gut microbiome compositions; however, a detailed mechanism has been unclarified. In this study, we showed their association with diabetes in addition to obesity, and further discovered a plausible mechanism of this association based on the function of commensal bacteria. First, we confirmed that the amylase copy number in the population tends to be larger than that reported in other studies and that there is a positive association between obesity and diabetes ( $p = 1.89E-2$  and  $8.63E-3$ ). Second, we identified that relative abundance of some genus level microbiome, *Capnocytophaga*, *Dialister*, and previously reported bacteria, were significantly associated with amylase copy numbers. Finally, through functional gene-set analysis using shotgun sequencing, we observed that the abundance of genes in the Acarbose pathway in the gut microbiome was significantly decreased with an increase in the amylase copy number ( $p$ -value =  $5.80E-4$ ). Our findings can partly explain the mechanism underlying obesity and diabetes in populations with high amylase copy numbers.

Similar to hundreds of human genes, the amylase genes reside in a structurally complex locus, with inversions, deletions, and many duplications. Copy number variation (CNV) of AMY genes, which encode amylase enzymes that digest starch into maltose and dextrin, is considered one of the strongest signals of recent natural selection in the human population. There are three amylase genes; the copy number of AMY1 (AMY1-CN), which encodes salivary amylase, varies from 1 to more than 20 copies, whereas the copy numbers of AMY2A (AMY2A-CN) and AMY2B (AMY2B-CN), which encode pancreatic amylase, vary from 1 to more than 6 copies. AMY1-CN is known to be positively correlated with salivary amylase activity and hydrolyzes the alpha bonds of starch and glycogen, initiating the process of starch degradation in the mouth. As the variety in the number of these genes is specific to agricultural races among humans, the CNVs of these three genes are hypothesized to shape the metabolic response to dietary starch<sup>1-3</sup>.

<sup>1</sup>Health Intelligence Center, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan. <sup>2</sup>Human Genome Center, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan. <sup>3</sup>Department of Biomedical Data Intelligence, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan. <sup>4</sup>Innovation Center for Health Promotion, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan. <sup>5</sup>COI Research Initiatives Organization, Hirosaki University, 5 Zaifu-cho, Hirosaki, Aomori, Japan. <sup>6</sup>Department of Social Medicine, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan. <sup>7</sup>Department of Stress Response Science, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan. ✉email: t-hasegw@ims.u-tokyo.ac.jp; imoto@ims.u-tokyo.ac.jp

In recent decades, several studies have shown that AMY1-CN and salivary amylase concentrations are associated with obesity and diabetes. Further, an increase in AMY1-CN levels is reported to decrease the risk of obesity<sup>4–9</sup>. However, some other studies have reported conflicting results and showed no or contrasting associations of AMY1-CN with obesity<sup>10–12</sup>. These conflicting results may be due to the heterogeneity in patient samples in terms of genetic background and lifestyle, as well as the use of different study methods, such as the assessment of AMY1-CN. Interestingly, Rukh et al. reported that the degree of dietary starch intake modifies the relationship between copy number variation in the salivary amylase gene and BMI; thus, an increase in AMY1-CN decreases the risk of obesity in the low starch intake group and increases the risk in the high starch intake group<sup>12</sup>. Marcovecchio et al. also showed that an increase in AMY1-CN decreases the risk of obesity in boys, but can increase its risk in girls<sup>9</sup>. Some other studies have shown that even though AMY1-CN is associated with salivary amylase levels, the salivary amylase level is more associated with obesity and BMI compared to AMY1-CN<sup>13–15</sup>.

Humans with high AMY1-CN (AMY1H), who can produce high levels of salivary amylase, might thus derive more energy from the same amount of diet compared to those with low AMY1-CN (AMY1L). Compared to AMY1H, AMY1L might be expected to harbor gut microbiomes with a greater capacity for the decomposition of carbohydrates. Thus, AMY1 copy number has also recently emerged as a significant factor in shaping the relative abundance of the specific members in the human oral and gut microbiome<sup>16–18</sup>. Further, an experimental study elucidated that the types of microbes in AMY1H drive higher adiposity when transferred to germ-free mice<sup>18</sup>, but the detailed mechanism has not been clarified.


In this study, we aimed to investigate the fundamental relationships of AMY1 and AMY2A with diabetes and obesity in a homogenous northern Japanese population considered to have a high starch intake. We first identified AMY1-CN, AMY2A-CN, and AMY2B-CN, and their mutation distributions using whole-genome sequencing data. In many studies, CNV arrays have been used to detect CNVs; however, recent studies suggest that whole-genome sequencing (WGS) analysis of CNVs is likely to be more efficient and outperforms array-based CNV analysis<sup>19</sup>. We utilized a methodology that has been developed to accurately estimate CNVs in AMY regions from sequencing data<sup>20,21</sup>. Secondly, we analyzed the association of the copy numbers of AMY genes (AMY-CN) with obesity and diabetes. We then analyzed the oral and gut microbiome at the genus level to discriminate high and low AMY-CN individuals using 16S rRNA gene sequence analysis. Finally, we obtained shotgun metagenomic sequencing data of the oral and gut microbiome to investigate the functional gene sets of starch degradation pathways that can be related to AMY-CN.

## Results

**Distribution of AMY1, AMY2A, and AMY2B copy number variation.** We first analyzed the WGS data to detect AMY-CN from 1461 individuals in the 2014 and 2015 participants. For estimating AMY-CN, we applied TIDDIT<sup>20</sup> and AMYCNE<sup>21</sup>, and then obtained AMY1A, AMY2A, and AMY2B CNs and their relationships, as illustrated in Fig. 1. In contrast to the average AMY1-CN 10.3 in this population, as described in Fig. 1a, previous studies have reported much smaller average AMY1-CN; for example, the average CN was 7 in a study from Qatar<sup>13</sup>, 8.3 in a study from Japan<sup>14</sup>, 7.9 in a study from the US<sup>18</sup>, and 7.0 in a study from Mexico<sup>16</sup>. As illustrated in Fig. 1b, AMY1 and AMY2A CNs were strongly correlated ( $r=0.60$ ,  $p=2.82E-144$ ) because their genetic regions are near and on the same linkage disequilibrium (LD) block<sup>11</sup>. On the contrary, AMY2B-CN was not associated, and almost all participants had two copies. Thus, we focused on AMY1 and AMY2A CNs in the following experiments.

**SNP patterns on AMY1, AMY2A and AMY2B regions.** Next, we summarized the SNP distributions in the AMY gene regions as shown in Table 1 and illustrated in Fig. 2. Contrary to the results of AMY CNV, the number of SNPs was clearly larger in the AMY2A and AMY2B regions than in the AMY1 region. However, a previous study reported that several SNPs with a minor allele frequency of more than 0.3, for example, rs42443712, were detected in the AMY1A region<sup>11</sup>. In addition, several SNPs discovered in our analysis did not have a reference SNP ID (rsID) assigned to an identical location. It could be that the genetic variety of AMY1A might not be observed because this cohort is from a region of Japan where genetic diversity appears to be low. Notably, even though the effects of these SNPs on BMI and HbA1c were investigated, no significant effect was detected, similar to a previous study<sup>11</sup>. Thus, we focused on the effects of AMY-CN in the following sections.


**Effect of AMY CN on Diabetes, Obesity, HbA1c and BMI.** Then, we performed a linear regression analysis of AMY1 and AMY2A CNs on diabetes, obesity, HbA1c and BMI with the explained covariates. According to the exclusion criteria, 578 and 676 participants were remained for the analysis. As a result, AMY1-CN and AMY2-CN were positively associated with diabetes, obesity, HbA1c and BMI, and their  $p$ -values for the first and second criteria of AMY1-CN and AMY2A-CN were 2.69E–2, 1.89E–2, 1.71E–2 for diabetes, 7.21E–1, 8.63E–3, 8.87E–2 for obesity, 1.34E–2, 1.95E–2, and 2.76E–2 for HbA1c and 4.71E–1, 3.28E–2, and 6.25E–2 for BMI, respectively. The number of participants with diabetes were 4/338 (low group) and 10/240 (high group) in AMY1-CN first criteria, 0/90 (low group), 10/417 (medium group), and 4/71 (high group) in AMY1-CN second criteria, and 2/276 (low group) and 12/302 (high group) in AMY2A-CN. The number of participants with obesity were 16/392 (low group) and 9/284 (high group) in AMY1-CN first criteria, 0/107 (low group), 19/486 (medium group), and 6/83 (high group) in AMY1-CN second criteria, and 9/326 (low group) and 16/350 (high group) in AMY2A-CN. The results for diabetes, obesity, HbA1c and BMI with AMY-CN are illustrated in Fig. 3. Using the predefined threshold ( $p=0.05$ ), we confirmed the statistically significant association of AMY1 and AMY2A CNs with diabetes and HbA1c. In addition, AMY1A in the second criterion tended to be associated with obesity and BMI. These results are partially consistent with those of a previous study<sup>12</sup>; further, the association with diabetes and HbA1c in the Japanese population seems to be a novel observation.



**Figure 1.** Histogram of AMY1, AMY2A, and AMY2B copy number variations and their associations. In the left of this figure, the histograms of AMY1A, AMY2A, and AMY2B-CN are displayed. The number of analyzed participants are also indicated at the top of each histogram. In the right of this figure, associations among AMY1A, AMY2A, and AMY2B-CN are illustrated as a scatter plot. At the top of each scatter plot,  $r$  and  $p$  indicate Pearson's correlation coefficient and  $p$ -value, respectively.

	Exonic (nonsynonymous, synonymous, top)	Intronic	UTR5	Splicing	Intergenic
AMY1	20 (19, 1, 0)	1,131	0	0	583,736
AMY2	564 (251, 292, 1)	13,253	113	1	13,456
AMY1-AMY2	-	-	-	-	1,229
Total	564	14,384	113	1	609,874


**Table 1.** Summary of SNPs detected in the AMY1, AMY2A, and AMY2B gene regions.



**Figure 2.** Distributions of SNPs on the exonic regions of AMY1, AMY2A, and AMY2B. In this figure, the vertical and horizontal axes indicate the number of participants with the corresponding SNPs and genomic positions including AMY1A, AMY2A, and AMY2B. Red, blue, green, black, and orange circles indicate nonsynonymous, synonymous, stop-gain (nonsense), splicing site, and 5' prime untranslated region mutations, respectively. The dot at the center of the circles indicates that the SNPs have reference SNP IDs. Genes corresponding to the positions are illustrated at the bottom of the figure.

**Association analysis between genus level microbiome composition and AMY CNs.** In this study, we obtained the oral and gut microbiome composition of the participants in 2015, 2016, 2017, and 2018 through 16S rRNA sequencing. Among these, we extracted the data from participants whose WGS was also obtained to calculate AMY-CN in 2014 or 2015. Considering the exclusion criteria, we selected 451, 487, 426, and 483 participants for the oral microbiome and 435, 475, 412, and 465 participants for gut microbiome analysis in 2015, 2016, 2017, and 2018, respectively. In the microbiome analysis, we excluded bacteria for which the sum of compositions of all participants was less than  $1.0E-5$  and (ii) those that were included in less than 3% of the participants each year. We thus retained 90 and 135 genus level bacteria for the oral and gut microbiome analyses, respectively. Thus, their predefined significant level with Bonferroni correction were  $0.05/90/3 = 1.85E-4$  and  $0.05/135/3 = 1.23E-4$ , respectively, including stratification by sex. Because it was difficult to integrate microbiome composition data over the entire study period, we calculated integrated p-values using fixed-effect meta-analysis based on the estimates and standard errors. Here, we focus on two prominent bacteria associated with AMY1-CN, as illustrated in Fig. 4. *Capnocytophaga* in the oral microbiome tended to be negatively associated with AMY1-CN ( $p = 1.38E-6$ ). In addition, the *Dialister* composition in the gut microbiome increased and decreased with the increase in AMY1 CNs for males and females, respectively, and these differences were statistically significant ( $p = 1.02E-6$  for males and  $6.00E-6$  for females). In particular, *Dialister* has been reported to be associated with carbohydrate metabolism and host diet; we could reproduce these results<sup>18,22</sup>. The top 10 bacteria and their p-values are presented in the supplementary material. On the other hand, there was no association between *Capnocytophaga* and *Dialister* compositions and diabetes or obesity. In addition, the same analysis was conducted after stratifying the *Dialister* compositions for factors other than gender (age, BMI, HbA1c, weight, systolic and diastolic blood pressure, LDL cholesterol, smoking, and alcohol consumption), but no significant results were obtained for these factors as illustrated in the supplemental material. In this analysis, in the case of continuous values, two groups were created based on the mean value.

**Functional gene abundance analysis.** Through the above experiments, AMY-CN can be associated with HbA1c levels, BMI, and the oral and gut microbiomes. To further investigate the underlying mechanisms, we analyzed the abundance of functional gene sets in the oral and gut microbiome in association with AMY-CN using shotgun microbiome sequencing. As we obtained data for 2015 and 2016, we considered participants whose WGS was obtained in 2014 and 2015. In this experiment, we generated the data by selecting the participants in 2015 and those participants in 2016 who did not participate in 2015, and integrating them into a single table. A total of 617 participants were thus included in this experiment. Because AMY-CN determine the capacity of amylase secretion, which decomposes starch into dextrin and maltose, we focused on the starch degradation pathway. In the KEGG pathway database<sup>23</sup>, we selected starch and sucrose metabolism (KEGG Identifier: map00500), amino sugar and nucleotide sugar metabolism (map00520), and Acarbose and validamycin biosynthesis (map00525) as potentially associated pathways. For this analysis, the total abundance of the gene set in each pathway was calculated for each participant, and a linear regression analysis with predefined covariates was also performed to analyze the association with AMY-CN. Here, the predefined p-value with




**Figure 3.** Association of Diabetes, Obesity, HbA1c and BMI with AMY1A and AMY2A-CN. In the upper and bottom parts of this figure, the associations of HbA1c and BMI with the criterion 1 and 2 of AMY1-CN and AMY2-CN are illustrated as barplots, respectively. In addition, the number of participants with diabetes and obesity is displayed on each barplot. The number of analyzed participants and p-values calculated using linear regression model for HbA1c and BMI and logistic regression model for diabetes and obesity with predefined covariates are displayed on the barplots.

Bonferroni correction was  $0.05/3 = 1.67E-2$ . As a result, the total abundance of genes in map0525 was negatively associated with AMY1-CN under the first and second criteria ( $p = 5.80E-4$  and  $3.97E-2$ , respectively) and with AMY2A-CN ( $p$ -value =  $1.15E-3$ ), as illustrated in Fig. 5. Acarbose is an oral hypoglycemic drug used for treating type 2 diabetes, and this decrease could increase blood glucose levels. On the other hand, there was no significant association between gene expression of map00525 pathway and serum glucose levels. Although we could not identify which functional genes were derived from which bacteria, we created a list of microbiome that could be associated with this pathway by using the genes in map00525 and the list of functional genes in the microbiome.

## Discussion and conclusion

Several studies published in the last decade have shown that AMY1-CN is associated with obesity and diabetes. In contrast, several studies have reported that no significant association was observed among them. These conflicting results may have been influenced by the selection of populations and their lifestyles. For example, in people who eat a low starch diet, a high percentage of salivary amylase digests starch quickly and serum glucose levels become quickly and temporarily high at an early stage, whereas a low percentage of amylase can maintain a high serum glucose level. On the contrary, for people who eat large amounts of starch, a high percentage of salivary amylase may result in high glucose levels, whereas a low salivary amylase level may maintain moderate serum glucose levels. For most human beings, grains and rice are a major source of energy. Thus, it is important to elucidate the impact and mechanism of AMY-CNV on obesity and diabetes.

First, we assumed that the residents of Hirosaki City consume a relatively large amount of starch, even in Japan. According to a survey of rice consumption in two or more households by the Statistics Bureau, Ministry of




**Figure 4.** Association of the oral and gut microbiome with AMY1-CN. In the upper, middle, and bottom panels of this figure, associations of the composition of *Capnocytophaga* for males and females, *Dialister* for males, and *Dialister* for females are illustrated by violin-plot. The number of analyzed participants for each year and the  $p$ -values calculated using linear regression models with predefined covariates are displayed on the plots.

Internal Affairs and Communications in Japan (<https://www.stat.go.jp/data/kakei/5.html>), the national average is 64.16 [kg/year], the consumption in Morioka city, which is close to Hirosaki city, is 71.61 [kg/year], whereas that in Tokyo is 53.16 [kg/year]; thus, the high starch consumption in this area might be related to this observation. Further, the AMY1A region has very few SNPs compared to the AMY2A and AMY2B regions. Thus, it seems that AMY1A exhibits diversity by copy number, and the AMY2A and AMY2B express diversity by mutation. However, in previous studies, more frequent SNPs in the AMY1 region have been reported; these results might thus be region-specific.

Similar to previous studies, we examined the association between AMY1-CN and HbA1c and BMI. The results showed that both HbA1c levels and BMI increased significantly with the increase in AMY1-CN. This is consistent with the finding of a positive correlation between the increase in AMY1-CN and BMI in the high starch intake group<sup>12</sup>, but the association with HbA1c levels is a new finding in the Japanese population. Further, because the average AMY1-CN in this study was clearly greater than that in other studies, there could be a positive selection that favored more AMY1-CN in the past.

AMY-CN is reported to have a strong correlation with amylase secretion, and has a stronger effect on BMI and the oral and gut microbiome. As the amount of amylase secretion was not measured in this study, we examined



**Figure 5.** Associations of abundance of the Acarbose pathway gene set. The associations of the total abundance of the gene-set in the Acarbose pathway (KEGG: map00525) to criterion 1 and 2 of AMY1-CN and AMY2-CN are illustrated as violin-plots. The number of analyzed participants and  $p$ -values calculated by linear regression models with predefined covariates are displayed on the plots.

the association between AMY1-CN and the oral and gut microbiome. Previously, the association of the human microbiome and AMY-CN and the effect of microbiome translocation with obesity have been reported<sup>16–18</sup>. Those studies have reported that *Prevotella* in the oral cavity and *Ruminococcus* in the gut increased with an increase in AMY1-CN. In our experiment, although not statistically significant, similar tendencies were observed. In particular, in this study, we found that *Capnocytophaga* decreased significantly in the oral cavity as AMY1-CN increased. *Capnocytophaga* is known to be associated with periodontal disease and could be affected by the amount of starch decomposition; however, to the best of our knowledge, no study has been published regarding its associations. In addition, *Dialister* increased significantly in men and decreased significantly in women with an increase in AMY1-CN. *Dialister* has been reported to increase in obese women, but we show a strong correlation with AMY1-CN rather than with BMI and HbA1c levels. The amount of *Dialister* may be thus directly affected by the amount of amylase secreted, which could result in obesity and other consequences.

Finally, we tried to elucidate the mechanism underlying the effect of the oral and gut microbiome on obesity and diabetes from the viewpoint of changes in the abundance of pathway-based functional genesets. The results showed that the total amount of acarbose and validamycin biosynthesis (map00525) decreased significantly with an increase in both AMY1-CN and AMY2A-CN. Acarbose is an oral hypoglycemic drug used for the treatment of type 2 diabetes, which delays starch breakdown to glucose by inhibiting the action of  $\alpha$ -glucosidase. Thus, glucose is absorbed more slowly into the body, and postprandial hyperglycemia can be suppressed. It helps to keep serum blood glucose levels low, which in turn contributes to lower HbA1c and BMI. In other words, in the group with a small number of AMY-CN, the expression of acarbose in the gut can be increased and the increase in blood glucose is suppressed; in contrast, with a large number of AMY-CN, the expression of acarbose is decreased and the increase in blood glucose is promoted. The observation is consistent with the results of oral administration of acarbose, as patients with higher AMY1A-CN had reduced amounts of acarbose pathway genes in the gut and higher HbA1c and BMI levels. Through this mechanism, we could partially explain the causes of an increase in HbA1c levels and BMI in the group with a large AMY-CN.

Within this study, we have collected blood tests, body composition, whole genome sequencing data, oral and gut microbiome abundance and functional gene abundance over time and comprehensively for a population in a limited area with similar social habits. Because microbiome compositions tend to change depending on the collection method and time, it is particularly important to analyze microbiome abundance with the same tendency throughout the years. On the other hand, since the same participants did not always participate throughout the year, duplicate and missing data tended to occur, and since we recruited a wide range of participants, many data could not be used due to exclusion criteria. In addition, we considered a particularly limited population in Japan, thus these results may be specific to lifestyle, genome, and the oral and gut microbiome, and may not be applicable to other populations. Since this study was an observational study, it is necessary to verify the relationship between the microbiome composition with the Acarbose pathway genes and diabetes and obesity. However, even in such a specific population, our findings are partially consistent with previous research, and novel findings on AMY-CN have been further obtained.

## Materials and methods

**Ethics statement.** This study design was approved by the Hirosaki University Hospital Institutional Review Board (Protocol Number Num. 2017-026). Written informed consent was obtained from all the patients in this study. All experiments were performed in accordance with relevant guidelines and regulations. No animal experiments were conducted in this study.

**Sample collection and preparation.** We analyzed the data obtained from the Hirosaki Center of Innovation (COI) health promotion project, which has collected cohort data from the year 2005 in Hirosaki (the population is approximately 10,000) in northern Japan. Each year, approximately 1000 people have their health status checked through a free participation program. The dataset actually has numerous missing data because the participants do not necessarily undergo a checkup each year. For example, some participants have participated in all years, while others have participated only once in any given year. Thus, the number of analyzed participants was displayed in each experiment. Questionnaires and blood tests were collected over the entire study period, and single nucleotide polymorphisms (SNPs) were identified for participants in 2014, 2015, 2016, and 2017; WGS analysis was performed for participants in 2014 and 2015; 16S rRNA sequencing of the oral and gut microbiomes was performed for participants in 2015, 2016, 2017, and 2018, and shotgun metagenomic sequencing of the oral and gut microbiomes was performed for participants in 2015 and 2016.

**Participant selection and covariate assessment.** The main exclusion criteria were as follows: (1) participants were younger than 18 years of age or were 55 older; (2) those with an estimated glomerular filtration rate (eGFR) below 60 [mL/min/1.73 m<sup>2</sup>] as calculated from serum creatinine levels and age at admission; (3) those with serum total bilirubin levels above 2 [mg/dL], (4) those with serum albumin levels above 35 [g/dL], (5) those with a BMI above 35 or below 18, (6) those who were prescribed medicine for diabetes mellitus as per their questionnaires, (7) those who were prescribed antidiabetic or antibiotic medication as per their questionnaires, for the analysis of oral and gut microbiome; and (8) those with missing information regarding any of their covariates. For medication, we considered the presence of medication at the time of checkup. For the determination of diabetic and obese participants, we adopted the criteria with HbA1c larger than 6.5 and BMI larger than 30, respectively. The flowchart of participant selection is illustrated in the supplementary material.

The participant covariate information was obtained from the blood value tests and questionnaires. The questionnaires were administered upon induction into the study. (a) Age and (b) sex information were obtained from questionnaires (sex was also checked using genetic data), (c) smoking status was classified as never (0) and current and former (1); (d) drinking status was classified as non-drinker (0), and current and former drinker (1). Participants who used medication for (e) high blood pressure, (f) dyslipidemia, (g) steroids, and (h) antibiotics were flagged as non-use (0) and use (1). Finally, we performed principal component analysis (PCA) for genotyping using the algorithm implemented in smartpca<sup>24</sup>, and used the top five principal components (PCs) as covariates to represent the population structure based on the genetic correlations among individuals.

In previous studies<sup>8–10</sup>, the expected effect size  $|r|$  of the correlation between AMY1-CN and obesity (BMI) has been estimated to be 0.416–0.512, although several studies have reported negative results for that correlation. Also, to our knowledge, no results have been reported on the association between AMY-CN and diabetes. Therefore, we assume that the target effect is moderate and that Cohen's effect size  $f$  is greater than 0.20. In this case, a regression model with a significance level of 0.05, a statistical power of 8.0E–1, and 14 coefficient would require a sample size of 471. In this study, there are 578 diabetic and 676 obese patients, of which 14 and 25 are cases, respectively. The analysis will also be conducted using BMI and HbA1c values as continuous values as the objective variables for obesity and diabetes, respectively.

**SNPs and whole genome sequencing.** DNA was purified from peripheral whole blood using a DNA extraction kit (QIAamp 96 DNA Blood Kit (QIAGEN, Hilden, Germany)) and was extracted from plasma pellets for SNP arrays and whole genome sequencing, respectively. SNP information was obtained from Japonica Array (Toshiba, Tokyo, Japan)<sup>25</sup> and comprised population-specific SNP markers designed from the 1070 whole genome reference panel<sup>26</sup>, and whole genome sequencing was performed by Takara Bio Corporation (Shiga, Japan).

**Analysis of AMY1, AMY2A, and AMY2B copy number variations.** To detect AMY1, AMY2A, and AMY2B CNVs from the WGS data, we used AMYCNE<sup>21</sup>, which was developed to estimate the AMY CNV from sequencing data. The input data for this software was prepared using TIDIT<sup>20</sup> which was also developed to clarify the structural variants.

**SNP analysis for AMY1, AMY2A, and AMY2B regions.** For SNP detection, we applied the Genomon pipeline (<https://github.com/Genomon-Project>), which has been developed to investigate mutations from exome/whole genome sequencing data. The filter conditions were as follows: minor allele frequency of 0.02 or higher, minimum read depth higher than 8, and 10% posterior percentile of the minor allele count based on a binomial distribution greater than 0.02, and a minimum base quality of 15 or higher.

**Microbiome assay.** Microbiome samples were obtained from participants' tongue plaques and stool samples for oral and gut microbiomes, respectively, and were stored at – 80 °C until use. The detailed library preparation method, including PCR conditions, has been described in a previous paper<sup>27</sup>. Briefly, the samples were mixed with zirconia beads and lysed using a FastPrep FP100A instrument (MP Biomedicals, Santa Ana, CA, USA). DNA was extracted from the bead-treated suspensions using a Magstration System 12GC and GC series MagDEA DNA 200 (Precision System Science, Chiba, Japan) and amplified. The 16S rRNA gene amplicons covering the V3–V4 region were sequenced using Pro341F and Pro805R primers. Sequencing was performed using a paired-end, 2 × 250-base pair cycle run on an Illumina MiSeq sequencing system. Shotgun metagenomic sequencing was performed on the HiSeq2500 instrument (Illumina, San Diego, CA, USA) with 101 bp paired-end reads.

**Calculation of genus level microbiome abundance profiles from 16S rRNA sequences.** Adapter sequences and low-quality bases at the 3'-end (threshold=30) were trimmed using Cutadapt (version: 1.13)<sup>28</sup> from paired-end reads obtained using the Illumina MiSeq sequencing system. In addition, the reads containing N bases and reads shorter than 150 bases were removed. The remaining reads were merged into single reads, and those with a length of 370–470 bases were removed using the VSEARCH<sup>29</sup> fastq\_mergepairs subcommand (version: 2.4.3). After merging, we removed reads that were expected to have one or more base errors from the base quality. After removing chimeric reads using the VSEARCH<sup>29</sup> uchime\_denovo subcommand, the reads were clustered with 97% sequence identity and the taxa of each cluster were identified using the RDP Classifier (git commit hash: (commit hash: 701e229dde7cbe53d4261301e23459d91615999d))<sup>30</sup>. At this time, the result with a confidence value < 0.8, was treated as unclassified. The relative abundance of each taxon was then calculated by dividing the number of reads belonging to the cluster to which the taxon was assigned by the total number of reads.

**Calculation of functional gene abundance from shotgun metagenomic sequencing.** Adapter sequence and low-quality bases at the 3'-end (threshold=30) were trimmed using Cutadapt (version: 1.13) from 2 × 100-base paired-end reads obtained using the Illumina HiSeq 2500 system. Reads containing N bases and reads shorter than 80 bp were removed. Reads from the host genome were also removed using BWA-MEM (version 0.7.15)<sup>31</sup> with GRCh38. From the remaining reads (referred to as non-host reads), contigs were generated by metagenomic assembly using MEGAHIT (version 1.1.1)<sup>32</sup>. The coding regions of genes on these contigs were predicted using Prodigal (version 2.6.3)<sup>33</sup>. After mapping the non-host reads to contigs using BWA-MEM, the relative abundances of the genes were calculated from the average depth of the gene region. KEGG pathway annotations were mapped to genes using a sequence similarity search with MMseqs2 (version: 1d2579627f43662e-caaa0778bd348fc35048976a)<sup>34</sup>. We used 1E-10 as the E-value threshold for the similarity search.

**Statistical analysis.** In the first criterion for AMY1-CN, participants were divided into low (AMY1-CN range 3–10) and high (AMY1-CN range 11–24) groups, which were separated at the center line. In the second criterion for AMY1-CN, participants were divided into the low (AMY1-CN range 3–7), medium (range 8–13), and high (range 14–24) groups. The minimum copy number above 10 percentile and the maximum copy number below 90 percentile of AMY1-CN distribution was 7 and 14, respectively. Similarly, for analyzing AMY2A-CN, participants were divided into low (AMY2A-CN range 1–2) and high (AMY2A-CN range 3–5) groups at the center line. When divided into two groups, we analyzed the effect of high AMY1-CN on the low AMY1-CN group. When divided into three groups. We compared participants in the top and bottom 10% of AMY1A-CN with the rest. Thus, we have analyzed the effect to groups with very high or low AMY1-CN relative to the subpopulation with a general number of AMY1-CN as control. We could not analyze the effect of AMY2B-CN because almost all patients had two AMY2B-CN. For these groups, linear regression analysis for continuous values and logistic regression analysis for binary values using the above-explained covariates was applied to detect statistical significance. A *p* value less than 0.05 was considered to indicate statistical significance when considering the corrections for multiple tests.

## Data availability

The datasets supporting the current study have not been deposited in a public repository [because the data are not public] but are available from the corresponding author, S.I., on request.

Received: 30 October 2021; Accepted: 18 April 2022

Published online: 10 May 2022

## References

- Pajic, P. *et al.* Independent amylase gene copy number bursts correlate with dietary preferences in mammals. *Elife*. <https://doi.org/10.7554/eLife.44628> (2019).
- Perry, G. H. *et al.* Diet and the evolution of human amylase gene copy number variation. *Nat. Genet.* **39**, 1256–1260. <https://doi.org/10.1038/ng2123> (2007).
- Inchley, C. E. *et al.* Selective sweep on human amylase genes postdates the split with Neanderthals. *Sci. Repv* **6**, 37198. <https://doi.org/10.1038/srep37198> (2016).
- Falchi, M. *et al.* Low copy number of the salivary amylase gene predisposes to obesity. *Nat. Genet.* **46**, 492–497. <https://doi.org/10.1038/ng.2939> (2014).
- Mejia-Benitez, M. A. *et al.* Beneficial effect of a high number of copies of salivary amylase AMY1 gene on obesity risk in Mexican children. *Diabetologia* **58**, 290–294. <https://doi.org/10.1007/s00125-014-3441-3> (2015).
- Bonnefond, A. *et al.* Relationship between salivary/pancreatic amylase and body mass index: A systems biology approach. *BMC Med.* **15**, 37. <https://doi.org/10.1186/s12916-017-0784-x> (2017).
- Elder, P. J. D., Ramsden, D. B., Burnett, D., Weickert, M. O. & Barber, T. M. Human amylase gene copy number variation as a determinant of metabolic state. *Expert Rev. Endocrinol. Metab.* **13**, 193–205. <https://doi.org/10.1080/17446651.2018.1499466> (2018).
- Viljakainen, H. *et al.* Low copy number of the AMY1 locus is associated with early-onset female obesity in Finland. *PLoS ONE* **10**, e0131883. <https://doi.org/10.1371/journal.pone.0131883> (2015).
- Marcovecchio, M. L. *et al.* Low AMY1 gene copy number is associated with increased body mass index in prepubertal boys. *PLoS ONE* **11**, e0154961. <https://doi.org/10.1371/journal.pone.0154961> (2016).
- Yong, R. Y. *et al.* Complex copy number variation of AMY1 does not associate with obesity in two East Asian Cohorts. *Hum. Mutat.* **37**, 669–678. <https://doi.org/10.1002/humu.22996> (2016).
- Usher, C. L. *et al.* Structural forms of the human amylase locus and their relationships to SNPs, haplotypes and obesity. *Nat. Genet.* **47**, 921–925. <https://doi.org/10.1038/ng.3340> (2015).

12. Rukh, G., Ericson, U., Andersson-Assarsson, J., Orho-Melander, M. & Sonestedt, E. Dietary starch intake modifies the relation between copy number variation in the salivary amylase gene and BMI. *Am. J. Clin. Nutr.* **106**, 256–262. <https://doi.org/10.3945/ajcn.116.149831> (2017).
13. Al-Akl, N., Thompson, R. I. & Arredouani, A. High plasma salivary alpha-amylase, but not high AMY1 copy number, associated with low obesity rate in Qatari adults: Cross-sectional study. *Sci. Rep.* **10**, 17918. <https://doi.org/10.1038/s41598-020-74864-6> (2020).
14. Higuchi, R., Iwane, T., Iida, A. & Nakajima, K. Copy number variation of the salivary amylase gene and glucose metabolism in healthy young Japanese women. *J. Clin. Med. Res.* **12**, 184–189. <https://doi.org/10.14740/jocmr4082> (2020).
15. Nakajima, K., Higuchi, R., Iwane, T. & Iida, A. The association of low serum salivary and pancreatic amylases with the increased use of lipids as an energy source in non-obese healthy women. *BMC Res. Notes* **13**, 237. <https://doi.org/10.1186/s13104-020-05078-2> (2020).
16. Leon-Mimila, P. *et al.* Low salivary amylase gene (AMY1) copy number is associated with obesity and gut Prevotella abundance in Mexican children and adults. *Nutrients*. <https://doi.org/10.3390/nu10111607> (2018).
17. Hjorth, M. F. *et al.* Pretreatment prevotella-to-bacteroides ratio and salivary amylase gene copy number as prognostic markers for dietary weight loss. *Am. J. Clin. Nutr.* **111**, 1079–1086. <https://doi.org/10.1093/ajcn/nqaa007> (2020).
18. Poole, A. C. *et al.* Human salivary amylase gene copy number impacts oral and gut microbiomes. *Cell Host Microbe* **25**, 553–564. <https://doi.org/10.1016/j.chom.2019.03.001> (2019).
19. Zhou, B. *et al.* Whole-genome sequencing analysis of CNV using low-coverage and paired-end strategies is efficient and outperforms array-based CNV analysis. *J. Med. Genet.* **55**, 735–743. <https://doi.org/10.1136/jmedgenet-2018-105272> (2018).
20. Eisfeldt, J., Vezzi, F., Olason, P., Nilsson, D. & Lindstrand, A. TIDDI, an efficient and comprehensive structural variant caller for massive parallel sequencing data. *F1000Res* **6**, 664. <https://doi.org/10.12688/f1000research.11168.2> (2017).
21. Eisfeldt, J., Nilsson, D., Andersson-Assarsson, J. C. & Lindstrand, A. AMYCNE: Confident copy number assessment using whole genome sequencing data. *PLoS ONE* **13**, e0189710. <https://doi.org/10.1371/journal.pone.0189710> (2018).
22. Muniz Pedrego, D. A. *et al.* Gut microbial carbohydrate metabolism hinders weight loss in overweight adults undergoing lifestyle intervention with a volumetric diet. *Mayo Clin. Proc.* **93**, 1104–1110. <https://doi.org/10.1016/j.mayocp.2018.02.019> (2018).
23. Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. *Nucleic Acids Res.* **28**, 27–30. <https://doi.org/10.1093/nar/28.1.27> (2000).
24. Price, A. L. *et al.* Principal components analysis corrects for stratification in genome-wide association studies. *Nat. Genet.* **38**, 904–909. <https://doi.org/10.1038/ng1847> (2006).
25. Kawai, Y. *et al.* Japonica array: Improved genotype imputation by designing a population-specific SNP array with 1070 Japanese individuals. *J. Hum. Genet.* **60**, 581–587. <https://doi.org/10.1038/jhg.2015.68> (2015).
26. Nagasaki, M. *et al.* Rare variant discovery by deep whole-genome sequencing of 1070 Japanese individuals. *Nat. Commun.* **6**, 8018. <https://doi.org/10.1038/ncomms9018> (2015).
27. Takahashi, S., Tomita, J., Nishioka, K., Hisada, T. & Nishijima, M. Development of a prokaryotic universal primer for simultaneous analysis of Bacteria and Archaea using next-generation sequencing. *PLoS ONE* **9**, e105592. <https://doi.org/10.1371/journal.pone.0105592> (2014).
28. Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. *EMBnet J.* **17**, 10–12 (2011).
29. Rognes, T., Flouri, T., Nichols, B., Quince, C. & Mahe, F. VSEARCH: A versatile open source tool for metagenomics. *PeerJ*. <https://doi.org/10.7717/peerj.2584> (2016).
30. Lan, Y. M., Wang, Q., Cole, J. R. & Rosen, G. L. Using the RDP Classifier to predict taxonomic novelty and reduce the search space for finding novel organisms. *PLoS One*. <https://doi.org/10.1371/journal.pone.0032491> (2012).
31. Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. [arXiv:1303.3997v2](https://arxiv.org/abs/1303.3997v2) (2013).
32. Li, D. H., Liu, C. M., Luo, R. B., Sadakane, K. & Lam, T. W. MEGAHIT: An ultra-fast single-node solution for large and complex metagenomics assembly via succinct de Bruijn graph. *Bioinformatics* **31**, 1674–1676. <https://doi.org/10.1093/bioinformatics/btv033> (2015).
33. Hyatt, D. *et al.* Prodigal: Prokaryotic gene recognition and translation initiation site identification. *BMC Bioinform.* <https://doi.org/10.1186/1471-2105-11-119> (2010).
34. Steinegger, M. & Soding, J. MMseqs2 enables sensitive protein sequence searching for the analysis of massive data sets. *Nat. Biotechnol.* **35**, 1026–1028. <https://doi.org/10.1038/nbt.3988> (2017).

## Acknowledgements

This work was supported by JST COI Grant Number JPMJCE1302. This research used the supercomputing resources provided by the Human Genome Center, Institute of Medical Science, University of Tokyo (<http://sc.hgc.jp/shirokane.html>).

## Author contributions

T.H. designed the study, analyzed the data, interpreted the data, and wrote the manuscript. M. K., R.Y., and N.S. analyzed the data, interpreted the data, helped write the manuscript, and commented on the drafts. T.M., K.M., S.N., and K.I. performed the medical checkups and gathered and summarized the data. S.I. interpreted the data, helped write the manuscript, commented on the drafts, and supervised the study. All authors have read and approved the final manuscript.

## Competing interests

The authors declare no competing interests.

## Additional information

**Supplementary Information** The online version contains supplementary material available at <https://doi.org/10.1038/s41598-022-11730-7>.

**Correspondence** and requests for materials should be addressed to T.H. or S.I.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022